Opening book details…
Can I read Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer on EtoBox?
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause is a nonfiction available to read on EtoBox.
What is Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer about?
## Background: Metastatic castration-resistant prostate cancer remains fatal despite recent advances. prostate-specific membrane antigen (psma) is highly expressed in metastatic castration-resistant prostate cancer. lutetium-177 (lu)-psma-617 is a radioligand therapy that delivers beta-particle radiation to psma-expressing cells and the surrounding microenvironment. ## Methods: We conducted an international, open-label, phase 3 trial evaluating lu-psma-617 in patients who had metastatic castration-resistant prostate cancer previously treated with at least one androgen-receptor-pathway inhibitor and one or two taxane regimens and who had psma-positive gallium-68 (ga)-labeled psma-11 positron-emission tomographic-computed tomographic scans. patients were randomly assigned in a 2:1 ratio to receive either lu-psma-617 (7.4 gbq every 6 weeks for four to six cycles) plus protocol-permitted standard care or standard care alone. protocol-permitted standard care excluded chemotherapy, immunotherapy, radium-223 (ra), and investigational drugs. the alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0
Who reads Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer?
It is typically read by self-directed learners exploring a subject in depth.
Common subject areas: history, science, philosophy, social sciences.
- Author
- Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
- Publisher
- The New England Journal of Medicine
- Published
- 2021
- Language
- EN
- Category
- nonfiction
- Subjects
- Medical, Oncology, Medicine
More by Oliver Sartor; Johann de Bono; Kim N Chi; Karim Fizazi; Ken Herrmann; Kambiz Rahbar; Scott T Tagawa; Luke T Nordquist; Nitin Vaishampayan; Ghassan El-Haddad; Chandler H Park; Tomasz M Beer; Alison Armour; Wendy J Pérez-Contreras; Michelle DeSilvio; Euloge Kpamegan; Germo Gericke; Richard A Messmann; Michael J Morris; Bernd J Krause
Similar books
- Circulating Tumour DNA Biomarkers Associated with Outcomes in Metastatic Prostate Cancer Treated with Lutetium-177-PSMA-617 — Crumbaker, Megan; Goldstein, Leonard D.; Murray, David H.; Tao, Jiang; Pathmanandavel, Sarennya; Boulter, Nicky; Ratnayake, Lalith; Joshua, Anthony M.; Kummerfeld, Sarah; Emmett, Louise (2023)
- 20 Questions and Answers About Metastatic Castration-Resistant Prostate Cancer (mCRCP) — Pamela Ellsworth; CHIRS (2014)
- Management of Castration Resistant Prostate Cancer (Current Clinical Urology) — Mario A. Eisenberger Fred Saad (2014)
- Hormone Therapy and Castration Resistance of Prostate Cancer (2018)
- Lutetium-177–PSMA-617 or Cabazitaxel in Metastatic Prostate Cancer: Circulating Tumor DNA Analysis of the Randomized Phase 2 TheraP Trial — Edmond M. Kwan & Sarah W. S. Ng & Sofie H. Tolmeijer & Louise Emmett & Shahneen Sandhu & James P. Buteau & Amir Iravani & Anthony M. Joshua & Roslyn J. Francis & Vinod Subhash & Sze-Ting Lee & Andrew M. Scott & Andrew J. Martin & Martin R. Stockler &... (2025)
- Drug Management of Prostate Cancer — William D. Figg, Cindy H. Chau, Eric J. Small, editors (2010)